中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 12
Dec.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(12): 2494-2498

Interpretation of expert consensus on the detection and clinical application of hepatitis C virus markers （2025 edition）

DOI: 10.12449/JCH251209

  • National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases，Beijing Key Laboratory of Viral Infectious Diseases，Department of Clinical Laboratory，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Beijing Hospitals Authority's Ascent Plan (DFL20241801)

More Information
  • Corresponding author: WANG Yajie， wangyajie@ccmu.edu.cn （ORCID： 0000-0002-3285-2537）
  • Received Date: 2025-10-12
  • Accepted Date: 2025-10-16
  • Published Date: 2025-12-25
    Abstract
  • In 2025， Expert Committee of the Clinical Laboratory Alliance， National Center for Infectious Diseases， organized related experts to develop Expert consensus on the detection and clinical application of hepatitis C virus markers （2025 edition）. This consensus outlines the objectives for hepatitis C prevention and control， identifies target populations for testing， and provides guidance on biomarkers， testing methods， and sample transportation. It also proposes optimized testing strategies tailored to the epidemiological characteristics of hepatitis C in China and the specific features of its diagnostic markers. The focus of this consensus is to address the shortcomings of traditional detection methods， such as prolonged window periods and missed diagnoses in immunocompromised populations， thereby improving the detection rate of hepatitis C. The consensus is of great importance for eliminating the public health threat of viral hepatitis in China. This article provides an interpretation of the consensus， in order to provide clearer practical guidance for the clinical testing of hepatitis C.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    Expert Committee of the Clinical Laboratory Alliance, National Center for Infectious Diseases. Expert consensus on the detection and clinical application of hepatitis C virus markers(2025 edition)[J]. Chin J Lab Med, 2025, 48( 9): 1125- 1133. DOI: 10.3760/cma.j.cn114452-20250425-00253.

    国家传染病医学中心临床检验联盟专家委员会. 丙型肝炎病毒标志物检测与临床应用专家共识(2025版)[J]. 中华检验医学杂志, 2025, 48( 9): 1125- 1133. DOI: 10.3760/cma.j.cn114452-20250425-00253.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.
    [3]
    ROGER S, DUCANCELLE A, LE GUILLOU-GUILLEMETTE H, et al. HCV virology and diagnosis[J]. Clin Res Hepatol Gastroenterol, 2021, 45( 3): 101626. DOI: 10.1016/j.clinre.2021.101626.
    [4]
    World Health Organization. Global hepatitis report 2024[EB/OL].( 2024-04-09)[ 2025-01-02]. https://www.who.int/pu blications/i/item/97892400-91672. https: //www.who.int/pu blications/i/item/97892400-91672
    [5]
    National Disease Control and Prevention Administration. Overview of the epidemic situation of notifiable infectious diseases in China[EB/OL].( 2025-01-16)[ 2025-01-20]. https://www.ndcpa.gov.cn/jbkzzx/c100016/common/list.html. https: //www.ndcpa.gov.cn/jbkzzx/c100016/common/list.html

    国家疾病预防控制局. 全国法定传染病疫情概况[EB/OL].( 2025-01-16)[ 2025-01-20]. https://www.ndcpa.gov.cn/jbkzzx/c100016/common/list.html. https: //www.ndcpa.gov.cn/jbkzzx/c100016/common/list.html
    [6]
    National Medical Quality Control Center for Infectious Diseases. Expert consensus on quality improvement of hepatitis C diagnosis and treatment[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2023, 17( 6): 385- 389. DOI: 10.3877/cma.j.issn.1674-1358.2023.06.005.

    国家感染性疾病医疗质量控制中心. 丙型病毒性肝炎诊治质量改进专家共识[J/CD]. 中华实验和临床感染病杂志(电子版), 2023, 17( 6): 385- 389. DOI: 10.3877/cma.j.issn.1674-1358.2023.06.005.
    [7]
    China CDC. Technical Guidelines for Laboratory Testing of Hepatitis C Virus(2023 Revision)[S/OL].( 2023-10-16)[ 2025-01-03]. https://www.chinacdc.cn/zxdt/202310/t20231018_270168.html. https: //www.chinacdc.cn/zxdt/202310/t20231018_270168.html

    中国疾病预防控制中心. 丙型肝炎病毒实验室检测技术规范(2023年修订版)[S/OL].( 2023-10-16)[ 2025-01-03]. https://www.chinacdc.cn/zxdt/202310/t20231018_270168.html. https: //www.chinacdc.cn/zxdt/202310/t20231018_270168.html
    [8]
    WANG YJ, CHEN Y, GUAN M, et al. National report on the current status and development needs of clinical laboratory testing for infectious diseases[J]. Chin J Lab Med, 2025, 48( 1): 38- 48. DOI: 10.3760/cma.j.cn114452-20240710-00363.

    王雅杰, 陈瑜, 关明, 等. 全国传染病临床检验现状与发展需求调研报告[J]. 中华检验医学杂志, 2025, 48( 1): 38- 48. DOI: 10.3760/cma.j.cn114452-20240710-00363.
    [9]
    Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35( 12): 2670- 2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2670- 2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
    [10]
    World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: Updated version[EB/OL].( 2016-04-13)[ 2025-09-15]. https://www.who.int/publications/i/item/9789241549615. https: //www.who.int/publications/i/item/9789241549615
    [11]
    YANG RF, LIU N, BIAN CR, et al. A multi-center performance evaluation of different hepatitis C virus core antigen assays for clinical infection screening[J]. Chin J Lab Med, 2023, 46( 12): 1305- 1312. DOI: 10.3760/cma.j.cn114452-20230718-00014.

    杨瑞锋, 刘宁, 卞成蓉, 等. 多种丙型肝炎病毒核心抗原试剂用于临床感染筛查的多中心性能评价[J]. 中华检验医学杂志, 2023, 46( 12): 1305- 1312. DOI: 10.3760/cma.j.cn114452-20230718-00014.
    [12]
    WANG YH, JIE W, LING J, et al. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection[J]. Clin Lab Analy, 2021, 35( 6): e23755. DOI: 10.1002/jcla.23755.
    [13]
    CARTY PG, MCCARTHY M, O’NEILL SM, et al. Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy[J]. Rev Med Virol, 2022, 32( 4): e2320. DOI: 10.1002/rmv.2320.
    [14]
    JANCZEWSKA E, ZARĘBSKA-MICHALUK D, BERAK H, et al. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors-a multicenter cohort study[J]. BMC Infect Dis, 2018, 18( 1): 580. DOI: 10.1186/s12879-018-3465-2.
    [15]
    CHANG C, HUNG CH, WANG JH, et al. Hepatitis C core antigen highly correlated to HCV RNA[J]. Kaohsiung J Med Sci, 2018, 34( 12): 684- 688. DOI: 10.1016/j.kjms.2018.08.002.
    [16]
    THOMSON EC, NASTOULI E, MAIN J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV[J]. Aids, 2009, 23( 1): 89- 93. DOI: 10.1097/qad.0b013e32831940a3.
    [17]
    VAN TILBORG M, MARZOOQI SH AL, WONG WWL, et al. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: Retrospective screening and diagnostic cohort studies[J]. Lancet Gastroenterol Hepatol, 2018, 3( 12): 856- 864. DOI: 10.1016/s2468-1253(18)30271-1.
    [18]
    ADLAND E, JESUTHASAN G, DOWNS L, et al. Hepatitis virus(HCV) diagnosis and access to treatment in a UK cohort[J]. BMC Infect Dis, 2018, 18( 1): 461. DOI: 10.1186/s12879-018-3367-3.
    [19]
    PROSTKO J, ROTHMAN R, HSIEH YH, et al. Performance evaluation of the Abbott Alinity Hepatitis C antigen next assay in a US urban emergency department population[J]. J Clin Virol, 2024, 175: 105743. DOI: 10.1016/j.jcv.2024.105743.
    [20]
    ROCKSTROH JK, FELD JJ, CHEVALIEZ S, et al. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients[J]. J Virol Meth, 2017, 245: 14- 18. DOI: 10.1016/j.jviromet.2017.03.002.
    [21]
    LIN SF, TUNG SY, WEI KL, et al. Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C[J]. PLoS One, 2020, 15( 3): e0229994. DOI: 10.1371/journal.pone.0229994.
    [22]
    ZHANG YQ, WANG J, CHANG JX, et al. Correlation and the clinical significance of hepatitis C virus RNA and hepatitis C core antigen[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2019, 13( 3): 185- 189. DOI: 10.3877//cma.j.issn.1674-1358.2019.03.003.

    张怡青, 王洁, 常静霞, 等. 丙型肝炎病毒RNA与核心抗原的相关性及其临床意义[J/CD]. 中华实验和临床感染病杂志(电子版), 2019, 13( 3): 185- 189. DOI: 10.3877//cma.j.issn.1674-1358.2019.03.003.
    [23]
    HANSOONGNERN P, PRATEDRAT P, NILYANIMIT P, et al. An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA[J]. PLoS One, 2023, 18( 6): e0287694. DOI: 10.1371/journal.pone.0287694.
    [24]
    FENG B, YANG RF, JIANG HJ, et al. Correlation analysis of hepatitis C virus core antigen and low viral loads: Can core antigen replace nucleic acid test?[J]. Clin Exp Med, 2020, 20( 1): 131- 141. DOI: 10.1007/s10238-019-00588-1.
    [25]
    ORGANIZATION WH. WHO guidelines for malaria, 30 November 2024[M]. World Health Organization, 2024. DOI: 10.2471/b09146.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (123) PDF downloads(80) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return